Rheumatology Buy and Bill: Working Capital for Biologics
Rheumatology buy and bill is one of the most cash-intensive parts of running an infusion practice. The practice purchases expensive biologic drugs up front, administers them to patients and then waits for payers to pay the claim. Until payment arrives, that cash is tied up in inventory and receivables.
For a busy infusion program, the gap can be large enough to strain payroll, rent and other obligations. This article explains how the buy-and-bill cash cycle works and how working capital financing may help. Billing, payer and pharmacy rules vary, and nothing here is legal, tax, billing or compliance advice.
How the Buy-and-Bill Cash Cycle Works
In a typical cycle, several steps happen before the practice is paid:
- The practice verifies benefits and obtains any required prior authorization
- Drug is ordered and paid for, often on supplier terms
- Inventory is stored until the patient’s appointment
- The drug is administered and the claim is submitted
- The payer processes the claim, sometimes with requests for more information
- Payment is received and posted, or the claim is appealed
Each step adds time. If supplier terms require payment before the payer pays, the practice effectively finances the drug for that period.
Why Rheumatology Buy and Bill Strains Cash
Several features of rheumatology make the cash cycle especially demanding:
- High drug costs: a single infusion can represent a substantial purchase
- Recurring schedules: patients return regularly, so inventory needs are ongoing
- Authorization requirements: delays or changes can disrupt scheduling and payment
- Denials and underpayments: each one extends the time cash is tied up
- Payment changes: payer policies and biosimilar adoption can shift margins
As an infusion program grows, the amount of cash needed to support it usually grows too. A practice can be profitable on paper and still feel short on cash.
Signs Your Practice Needs More Working Capital
Practices often notice warning signs before a cash shortage becomes serious:
- Delaying drug orders or rescheduling infusions because of cash timing
- Stretching supplier payments beyond agreed terms
- Relying on personal funds to cover payroll
- Rising accounts receivable without a matching rise in collections
- Difficulty adding chairs or staff despite patient demand
Working Capital Options for Rheumatology Buy and Bill
Depending on the practice’s financial profile, options may include:
- Revolving line of credit: draw to buy inventory, repay as claims are paid and draw again as needed
- Working capital term loan: a lump sum to build a cash reserve or support a larger program
- SBA-backed working capital: available in some cases, depending on eligibility, program rules and lender review
A rheumatology working capital line of credit can be structured to match the rhythm of drug purchases and payer payments. Our page on working capital solutions describes the broader range of options. Every loan is subject to approval, and nothing here is a commitment to lend.
How Lenders View Drug Inventory and Receivables
Lenders typically want to understand both the size and the quality of the cash cycle. They may review accounts receivable aging, collection history by payer, denial patterns, inventory levels and supplier terms. Practices with organized billing, timely collections and diversified payers tend to present a clearer picture.
Lenders may also consider how exposed the practice is to payment changes for a few high-cost drugs. Our article on rheumatology drug reimbursement risk explains this in more detail.
Operational Steps That Can Ease Cash Pressure
Financing is only one part of the solution. Practices often improve their position by tightening operations, with input from qualified billing professionals:
- Verifying benefits and authorizations well before appointments
- Tracking inventory to avoid excess stock and waste
- Reviewing supplier terms and purchasing arrangements
- Monitoring denials and working appeals promptly
- Reconciling payments against expected amounts
Planning for Growth
If you plan to add chairs or open a new rheumatology infusion suite, build working capital into the budget from the start. The construction and equipment costs are visible, but the inventory and receivables needed to operate the expanded program can be just as significant.
When Existing Debt Gets in the Way
Some practices find that high payments on existing loans leave too little room for inventory. In those cases, reviewing the overall debt structure may help. Our article on how to refinance rheumatology practice debt explains how practices approach this. Lenders will look at the full picture, so it can help to understand rheumatology practice loan requirements before applying.
Estimating How Much Working Capital You Need
A simple way to frame the need is to look at how much drug the practice buys over a typical period and how long it takes, on average, to collect after administration. The longer the gap and the larger the volume, the more cash the program requires.
Practices often work with their accountant to estimate:
- Average inventory on hand at any time
- Average time from drug purchase to payer payment
- The effect of denials and appeals on collection timing
- Planned growth in infusion volume
Having these figures ready can help a lender size a line of credit that fits the practice rather than one that is too small to help or larger than the practice needs.
Final Thoughts
Rheumatology buy and bill can support patient care and practice revenue, but it requires significant cash to carry inventory and receivables. Understanding the cycle, managing it carefully and arranging appropriate working capital can help a practice keep infusions on schedule.
US Medical Funding helps rheumatology practices arrange working capital for infusion programs. Learn more about our full range of rheumatology practice financing options.
